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Primary tracheal mucosa-associated lymphoid tissue (MALT) lymphoma is extremely rare. We report a 49-year-old
female patient with the complaint of dyspnea. Fiberoptic bronchoscopy showed polypoid, variable-sized and
irregular nodules causing narrowing of the tracheal lumen from the proximal trachea to the left main bronchus.
Because of severe stenosis in the airway and the severity of symptoms, this case was unresectable. The patient was
then treated successfully with placement of an endobronchial stent through bronchofibroscopy. After the
placement of the stent, bronchoscopic biopsy was performed. Pathological analysis confirms a diagnosis of MALT-
associated malignant lymphoma. We performed systemic chemotherapy on the patient. The temporary stent was
removed after the reduction of the stenosis. This is the first case in which tracheal MALT lymphoma was treated
successfully following tracheal stent insertion guided by bronchofibroscopy. Temporary tracheal stenting can be a
favorable choice for a patient with tracheal stenosis caused by primary tracheal MALT lymphoma.
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Mucosa-associated lymphoid tissue (MALT) lymphoma
is a distinct subgroup of non-Hodgkin’s lymphoma
(NHL) that comprises more than two-thirds of all pri-
mary NHL of the lung [1]; however, primary tracheal
MALT lymphoma is quite rare. Thus, there is no guide-
line for the treatment of the disease. Surgery, chemo-
therapy, and radiation therapy usually are selected
according to the clinical stage. This is the first report of
primary tracheal MALT lymphoma in China that was
successfully treated with temporary tracheal stent inser-
tion guided by bronchoscopy and systemic chemothe-
rapy. A review of the literature regarding primary MALT
lymphoma is provided to better define the clinical char-
acteristics and management of this uncommon disease.Case presentation
A 49-year-old woman was referred to our hospital with
the complaint of dyspnea for 4 years and increasing
symptoms over the last 2 months. She did not present
with night sweats or fever. Her medical, smoking and* Correspondence: dingjuanhai@163.com
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reproduction in any medium, provided the orfamily histories were all noncontributory. Inspiratory
and expiratory coarse rhonchi were auscultated over the
lung. Her other physical examination was unrevealing. A
computed tomography (CT) scan of the chest showed
soft tissue masses adjacent to the trachea and causing
diffuse narrowing of the tracheal lumen; however, there
was no evidence of mediastinal lymphadenopathy
(Figure 1). Fiberoptic bronchoscopy showed polypoid,
variable-sized and irregular nodules causing narrowing
of the tracheal lumen from the proximal trachea to the
left main bronchus (Figure 2A). Because of the severe
stenosis of the airway, the body of the fiberoptic bron-
choscope failed to pass the lumen of the trachea. The
risk when using an Nd:YAG laser and high frequency
electrocautery via bronchofibroscopy is high. Thus, we
decided to place the endobronchial stent in the trachea
(Figure 2B). After the successful placement of stent,
bronchoscopic biopsy was performed. The histological
finding indicated a dense proliferation of lymphoid cells
beneath the intact tracheal mucosa. The shape and size
of these lymphoid cells are almost identical (Figure 3).
The immunohistochemical results showed the presence
of markers LCA, CD20, Pax-5 and CD43, and the
absence of CD5 and CD23 (Figure 4). Pathological ana-
lysis confirms a diagnosis of MALT-associated malignantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography (CT) scan of the chest showed multiple soft tissue masses adjacent to the trachea, causing diffuse
narrowing of the tracheal lumen. (A) pulmonary window. (B) mediastinal window.
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performed a contrast-enhanced CT scan of the abdomen
and chest. There was no evidence of lymphoma involve-
ment. The patient received a bone marrow biopsy, a
gastric fibroscopy, and a color Doppler ultrasound of the
neck. These examinations revealed no abnormalities.
Next, the patient was given six courses of CHOP chemo-
therapy (cyclophosphamide 750 mg/m2 day 1, adriamycin
50 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednis-
one 100 mg/day 1 to 5, q 3 weeks). The tracheal stent was
extracted after 35 days after the patient had been given
one course of chemotherapy. Currently, the patient has
been well without any symptoms of recurrence for 12
months since the initial diagnosis.
Discussion
In 1984, Isaacson and Wright [2] described extra-nodal
lymphomas arising from MALT. Although MALT lymph-
oma occurs most frequently in the gastrointestinal tract, they
can also rise in various non-gastrointestinal sites, such as the
salivary gland, conjunctiva, thyroid, orbit, lung, breast,
kidney, skin, liver, uterus, and prostate [3]. Among the non-
gastrointestinal MALT lymphomas, the pulmonary lym-
phomas are the most frequent, with figures of up to 19%
among MALT lymphomas [4]. In spite of this, a primary
presentation of MALT lymphoma affecting the trachea is
very rare. Most reports in the literature are case reports.Figure 2 The presentation of fibrobronchoscopy showed polypoid, va
from the proximal trachea to the left main bronchus (A). The patency of thClinical features of MALT-derived lymphomas include a
tendency to remain localized for prolonged periods, and,
thus, to be responsive to locally directed therapy. Owing
to the rarity of the primary tracheal MALT lymphoma,
standard treatment protocols have not yet been optimized.
Local treatment such as surgical resection, radiotherapy
and intervention therapy by bronchofibroscopy are gener-
ally efficacious, and comprehensive treatment is preferred.
We present the case of a female patient with primary
tracheal MALT lymphoma who was treated successfully
with the placement of a temporary endobronchial stent
through the use of fiberoptic bronchoscopy, followed by
systemic chemotherapy.
Typically, in these cases, fiberoptic bronchoscopy
shows intratracheal polypoid lesions with the tracheal
lumen narrowing in one lumen. However our patient
presented with the lesions localized from the trachea to
the left main bronchus. This case has characteristics in
common with the case reported by Kang et al. [5],
whose case showed multiple, variable-sized nodules
causing bronchial narrowing from the proximal trachea
to bronchi of both lungs, including the carina. The
lesions of both of these cases are systemic disseminated.
To relieve airway obstruction and provide opportu-
nities for bronchoscopic biopsy in our case, we placed a
self-expanding metal stent via flexible bronchoscopy in
the trachea. To our knowledge, this is the first case ofriable-sized and irregular nodules. Narrowing of the tracheal lumen
e lumen after stent implantation (B).
Figure 3 Microscopic appearance of tracheal tissue
(hematoxylin and eosin stain, 200x) showing proliferation of
lymphoid cells beneath the intact tracheal mucosa.
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Temporary airway stenting has been extensively performed
to palliate dyspnea caused by extrinsic compression,
intraluminal disease, and loss of cartilaginous support. It is
not a cure, but is used mainly to help patients with various
diseases breathe better. Bernd et al. [6] investigated this
strategy of temporary airway stenting in five consecutive
patients with malignant lymphoma who presented with
severe dyspnea. The results show that temporary stenting
is a valuable strategy in chemo- and radiosensitive malig-
nancies, as it ameliorates the patient’s respiratory condition
until tumor-specific therapy is effective. Numerous studiesFigure 4 The immunohistochemical results (DAB, 400x) showed the phave reported that endobronchial therapies, including air-
way stenting, can palliate symptoms in 80 to 97% of
patients with dyspnea [7]. Patients with significant central
airway obstruction are frequently within hours or days of
dying due to suffocation [8]. Airway resection and recon-
struction provides the most reliable definitive correction,
but many patients are unresectable. For these patients
therapeutic bronchoscopy provides rapid palliation that
can be lifesaving and improve quality of life. In general,
temporary tracheal stenting as palliation treatment can be
a favorable choice for a patient with tracheal stenosis by
primary tracheal MALT lymphoma. Also, it is an integral
part of multi-therapy methods.
Conclusions
In conclusion, primary tracheal MALT lymphoma is seen
rarely, but it responds well to therapies such as surgery,
chemotherapy, and radiation therapy, used either alone or
in combination. Temporary tracheal stenting followed by
chemotherapy and/or radiotherapy is beneficial in the
management of tracheal lymphoma with symptomatic air-
way stenosis, as in this case.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal. This study
is retrospective, and it is approved by the ethics board.resence of markers. LCA (A), CD20 (B), Pax-5 (C) and CD43 (D).
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